On Wednesday the ASX small-cap healthcare stock gained another 7.8% at $2.20, bringing this year's gain to 44%.

Investors are clearly backing what the ASX healthcare share is building in a US$10 billion market. And is there more to come?

Global first in cardiac care

Imricor has been carving out a few global firsts in cardiac care recently. The US-based medical technology business focuses on MRI-guided cardiac ablation and claims to be the first to deliver commercially viable MRI-compatible consumables for these procedures.

Last month the ASX healthcare share announced that its NorthStar Mapping System is the first MRI-native 3D mapping and guidance system cleared by the FDA. It also marks Imricor's first capital equipment and first software-driven approval in the US.

This wasn't an overnight win. Imricor says NorthStar's FDA clearance caps years of R&D, third-party collaboration, and regulatory heavy lifting. The system is built to anchor every interventional cardiac MRI (iCMR) lab as its central hub.

Multiple clearances expected

Crucially, FDA approval opens the door to commercial sales of NorthStar in the United States — the world's largest electrophysiology market. And the pipeline isn't slowing.

Management expects multiple regulatory clearances this year as it rolls out its full MRI-guided electrophysiology platform. Investors in the ASX healthcare share are eagerly awaiting what management will reveal on 25 February when it delivers its second-half 2025 results.

Management said NorthStar's clearance was the company's second FDA win. It followed 510(k) approval for the VisionMR Diagnostic Catheter earlier in January. The approval further cements Imricor's push to lead the MRI-guided interventional market.

Technology that matters

The innovations of the ASX healthcare share matter. Traditional ablation relies on X-ray guidance. Imricor's iCMR platform lets doctors see the heart in real time using MRI.

That means better soft tissue visibility, no radiation exposure, and potentially better outcomes. If adoption builds, MRI-guided ablation could shift from niche to standard practice.

What next for the ASX healthcare share?

In March last year, the medical company raised $70 million to fund global expansion, commercial growth and R&D. Imricor isn't thinking small. It is rolling out across four key regions: the US, Australia and New Zealand, the Middle East, and Europe, where it holds CE Mark approval.

It's expanding into Germany, the Netherlands, France and Italy, running more US trials to secure FDA clearance, and has already signed exclusive distribution deals in the Middle East, including first sales in Qatar.

Analyst coverage is limited. TradingView data show that 3 brokers rate the $660 million ASX healthcare a strong buy. They have set an average 12-month price target of $2.49, which points to a 13% upside.

The most bullish analyst sees a possible gain of 26% for the next 12 months.  

The post Is there no stopping this groundbreaking ASX healthcare share? appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

Appen Ltd (ASX: APX)

The Appen share price is up 12% to $1.88. Investors have been buying this artificial intelligence data services company's shares since the release of a strong quarterly update last week. Appen reported revenue of $73.4 million for the three months. This was a 10% lift on the prior corresponding period and a 33% increase on the third quarter of FY 2025. Commenting on the quarter, Appen's CEO, Ryan Kolln, said: "Q4 was a strong finish to the year for both our China and Global businesses. Appen China exited the quarter with an annualised revenue run-rate growing to over $135 million – a pleasing result, providing strong momentum heading into FY26."

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 2% to $1.99. This morning, this medical device company revealed that Oklahoma Heart Institute (OHI) has joined the VISABL-AFL clinical trial. It notes that this will support the U.S. FDA approval process for Imricor's ablation products. OHI is now the fourth U.S. site to join the trial. Imricor's Chair and CEO, Steve Wedan, added: "Oklahoma Heart Institute represents a highly sophisticated cardiology-led model of care, with the clinical vision and infrastructure already in place to support advanced MRI-guided procedures. The fact that cardiology owns and operates their MRI system creates a streamlined environment for innovation, reducing organisational complexity while enabling physicians to focus on delivering the best possible outcomes for patients."

Qoria Ltd (ASX: QOR)

The Qoria share price is up 19% to 40 cents. This follows news that the cyber safety company is merging with its peer, Aura. It is a US-based provider of intelligent online safety solutions to individuals and families. Aura will acquire all Qoria shares through an all-scrip deal at a price equivalent to 72 cents per share. Qoria's CEO, Tim Levy, said: "The internet was created to connect us, yet online safety has eroded, making trust paramount for parents, guardians and organisations, in general, for the protection of our activities online. The combination of Aura and Qoria pioneers a lifelong digital safety ecosystem; a new category that meets the urgent need for technology, education, and trust to protect people – confidently and safely, throughout their entire lives."

Xero Ltd (ASX: XRO)

The Xero share price is up 3% to $96.46. Investors have been buying this cloud accounting platform provider's shares following the release of an update on its AI and US plans. Xero also reiterated its FY 2026 guidance. It advised that total operating expenses as a percentage of revenue is expected to be around 70.5%, including the Melio business. In addition, management reaffirmed its aim of more than doubling its FY 2025 group revenue in FY 2028.

The post Why Appen, Imricor, Qoria, and Xero shares are storming higher today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is down 2% to $2.01. This may have been driven by profit-taking from investors following a strong gain on Thursday. Investors were buying the medical device company's shares after it received US FDA approval for its NorthStar Mapping System. NorthStar is the first and only MRI-native 3D mapping and guidance system to receive FDA clearance. Imricor's chair and CEO, Steve Wedan, commented: "At Imricor, we have been building a comprehensive suite of uniquely MRI-compatible devices for two decades. These devices, which include both consumable products and capital equipment, enable doctors to harness the superior soft tissue imaging of MRI to precisely guide minimally invasive procedures in a 100% radiation-free setting."

Ioneer Ltd (ASX: INR)

The Ioneer share price is down 18% to 17 cents. Investors have been selling this lithium developer's shares after it raised capital. Ioneer revealed that it has received firm commitments from institutional, professional, and sophisticated investors to raise approximately US$50 million (approximately A$72 million) at a discount of 18 cents per new share. The company's executive chair, James Calaway, said: "The result of this offering is a strong endorsement of Ioneer's strategy and the market's understanding of the unique value and importance of Rhyolite Ridge to help onshore U.S. critical minerals production. This funding milestone allows us to aggressively move towards commencing construction and advancing discussions with potential strategic partners."

Star Entertainment Group Ltd (ASX: SGR)

The Star Entertainment share price is down 12.5% to 14 cents. This follows the release of the casino and resorts operator's quarterly update. Star reported a 6% increase in revenue to $301 million and positive group EBITDA of $6 million. The latter compares to an EBITDA loss of $13 million in the first quarter. It seems that the market was expecting even more from Star Entertainment.

Whitehaven Coal Ltd (ASX: WHC)

The Whitehaven Coal share price is down 4% to $9.06. This may have been driven by a broker note out of Bell Potter this morning. According to the note, the broker has downgraded the coal miner's shares to a sell rating with an $8.40 price target. It said: "We move to a Sell recommendation with strong recent share price performance. In the medium term, WHC are positioned to capitalise when coal markets sustainably improve with a diversified portfolio of assets in Queensland and New South Wales and strong organic growth optionality."

The post Why Imricor, Ioneer, Star, and Whitehaven Coal shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Appen Ltd (ASX: APX)

The Appen share price is up 27% to $1.38. Investors have been buying the artificial intelligence data services company's shares following the release of a strong quarterly update. Appen reported revenue of $73.4 million. This was a 10% lift on the prior corresponding period and a 33% increase on the third quarter of FY 2025. Appen's CEO, Ryan Kolln, said: "Q4 was a strong finish to the year for both our China and Global businesses. Appen China exited the quarter with an annualised revenue run-rate growing to over $135 million – a pleasing result, providing strong momentum heading into FY26."

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 11% to $2.11. The catalyst for this has been news that the medical device company has received US FDA approval for its NorthStar Mapping System. NorthStar is the first and only MRI-native 3D mapping and guidance system to receive FDA clearance. Imricor's chair and CEO, Steve Wedan, said: "At Imricor, we have been building a comprehensive suite of uniquely MRI-compatible devices for two decades. These devices, which include both consumable products and capital equipment, enable doctors to harness the superior soft tissue imaging of MRI to precisely guide minimally invasive procedures in a 100% radiation-free setting."

Sunrise Energy Metals Ltd (ASX: SRL)

The Sunrise Energy Metals share price is up 2.5% to $10.36. This follows the release of the company's quarterly update this morning. Management took this opportunity to remind investors about the progress it is making. It highlights that its Syerston scandium deposit is currently the world's largest and highest-grade source of mineable scandium on a granted mining lease adjacent to excellent infrastructure.

Whitehaven Coal Ltd (ASX: WHC)

The Whitehaven Coal share price is up 2.5% to $9.42. This morning, this coal miner released its quarterly update and revealed a 21% quarter on quarter increase in managed ROM production to 11Mt. Also increasing strongly were its equity sales, which rose 18% to 7Mt. Management also advised that it is on track to deliver $60 million to $80 million of annualised cost savings by 30 June 2026.

The post Why Appen, Imricor, Sunrise Metals, and Whitehaven Coal shares are charging higher today appeared first on The Motley Fool Australia.

At the time of writing, this ASX stock is up 18% to a 52-week high of $2.25.

Why is this ASX stock jumping today?

Investors have been bidding this medical device company's shares higher today after it made a big announcement.

According to the release, the United States Food and Drug Administration (FDA) has granted 510(k) clearance for the company's NorthStar Mapping System under the premarket notification process.

NorthStar is the first and only MRI-native 3D mapping and guidance system to receive FDA clearance. It is Imricor's first capital equipment and first software-centric product approval in the United States.

Management notes that this marks the ASX stock's second FDA clearance, after receiving 510(k) clearance for the VisionMR Diagnostic Catheter earlier this month. It believes the approval significantly strengthens Imricor's position as the market leader in MRI-guided interventional procedures.

This was no overnight success. The company highlights that NorthStar's clearance by the U.S. FDA marks the culmination of years of research, development, 3rd party partnerships, and regulatory work. The system is designed and intended to be the central hub of every interventional cardiac MRI lab (iCMR).

And there may be more to come. Management is expecting multiple regulatory clearances and approvals this calendar year, as its full MRI-guided electrophysiology platform is progressively introduced to the market.

This FDA clearance enables the ASX stock to commercially market NorthStar in the United States, which is the world's largest electrophysiology market.

Commenting on the news, Imricor's chair and CEO, Steve Wedan, said:

At Imricor, we have been building a comprehensive suite of uniquely MRI-compatible devices for two decades. These devices, which include both consumable products and capital equipment, enable doctors to harness the superior soft tissue imaging of MRI to precisely guide minimally invasive procedures in a 100% radiation-free setting. Our goal is to enable better, faster, safer and less expensive treatments for patients worldwide; and as the world's largest market, the United States is critical to our goal.

When it comes to iCMR procedures, NorthStar is the central hub that brings everything together. It's designed to not only facilitate diagnostic cardiac electrophysiology and ablations procedures, but also to provide MRI guidance capabilities for other procedures. And since NorthStar is primarily a software product, it ushers in Imricor's software era in which AI will play a big role in the future. NorthStar's platform provides a path for capability expansion that is virtually unlimited, and we will continue to invest in and expand its capabilities for years to come.

The post Guess which ASX stock is jumping 18% on FDA approval news appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are storming higher:

Develop Global Ltd (ASX: DVP)

The Develop Global share price is up 7% to $5.30. Investors have been buying this mining and mining services company's shares following the release of a bullish broker note out of Bell Potter. According to the note, the broker has retained its buy rating on the company's shares with an improved price target of $5.80. This implies further potential upside of 9.5% over the next 12 months. It said: "With Woodlawn de-risking behind us, DVP presents a unique small-cap copper-zinc exposure that is relatively undervalued compared with peers in the Resources space."

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 18% to $1.86. This has been driven by news that the medical device company has received clearance by the US Food and Drug Administration (FDA) for its Vision-MR Diagnostic Catheter. The catheter is designed to be used under real-time magnetic resonance imaging (MRI) guidance. Imricor's CEO, Steve Wedan, said: "This is obviously a tremendous milestone for the Imricor team, and I want to acknowledge the outstanding work of the entire team in reaching this achievement. Most of us have worked at companies that have existing medical devices on the US market, and getting a new device on the market is always a big deal."

Light & Wonder Inc (ASX: LNW)

The Light & Wonder share price is up 16% to $179.10. Investors have been fighting to get hold of the gaming technology company's shares after agreeing to pay $190 million to settle the Aristocrat Leisure Ltd (ASX: ALL) litigation. Light & Wonder's CEO, Matt Wilson, said: "Light & Wonder is pleased to resolve this matter and move forward. We are firmly committed to doing business the right way – respecting our competitors' intellectual property rights while protecting our own rights. This matter arose when a former employee inappropriately used certain Aristocrat math without our knowledge and in direct violation of our policies."

PWR Holdings Ltd (ASX: PWH)

The PWR Holdings share price is up over 10% to $9.64. This morning, this advanced cooling products and solutions provider announced a US$9.1 million (~A$13.5 million) follow-on defence and aerospace contract. This will see it supply advanced cooling solutions for a US government project. The company's acting CEO, Matthew Bryson, said: "PWR announced the initial US$5.5 million order for this project in January 2025 and securing a follow-on order reflects the successful delivery of that first phase and demonstrates our ability to execute reliably and adapt to evolving program requirements on complex projects."

The post Why Develop Global, Imricor Medical, Light & Wonder, and PWR shares are storming higher today appeared first on The Motley Fool Australia.

Imricor shares traded as high as $1.99 on the news, up more than 25%, before settling back to be 16.5% higher at $1.84.

The biotechnology company said in its statement to the ASX that the US Food and Drug Administration (FDA) had granted clearance for its Vision-MR Diagnostic Catheter, which would allow it to be marketed in the US.

ASX biotech medical innovation

The catheter, the company said, is designed to be used under real-time magnetic resonance imaging (MRI) guidance, "and represents a key component of Imricor's comprehensive platform of MRI-compatible electrophysiology (EP) devices''.

The company went on to say:

FDA clearance enables Imricor to commercially market the Vision-MR Diagnostic Catheter in the United States, the world's largest electrophysiology market. This clearance is the first of what the Company expects will be multiple regulatory clearances and approvals this calendar year, as Imricor's full MRI guided EP platform is progressively introduced to the market.

Imricor Chief Executive Officer Steve Wedan said it was a "tremendous milestone for the company" and added:

Most of us have worked at companies that have existing medical devices on the US market, and getting a new device on the market is always a big deal. But getting a company's first device on the US market is an extraordinarily big deal. It's an exciting achievement and a date to be noted and remembered.

ASX biotech product suite growing

The company, in its most recent quarterly report, said it had also submitted its NorthStar Mapping System – another real-time MRI product – for FDA approval, with that product already commercially launched in Europe following CE Mark approval.

Mr Wedan said at the time the company was entering the most exciting chapter in its 20-year history.

This was a milestone quarter for Imricor as we achieved parallel regulatory submissions in the US and launched NorthStar comedically in Europe. In Europe we are already seeing strong momentum following CE Mark approval of NorthStar … with growing demand from hospitals eager to perform cardia ablations in a radiation-free environment.

Imricor's cash outflows during the September quarter were US$4.8 million, while the company's total cash and short-term investments were worth US$45.7 million.

Total receipts for the quarter came in at US$124,000.

Imricor was valued at $503.9 million at the close of trade on Friday.

The post Which biotech company's shares have rocketed to a new high on good news? appeared first on The Motley Fool Australia.

Here's how.

ASX All Ords stock on the growth path

The first stock that looks well-placed to surge higher is Intelligent Monitoring Group Ltd (ASX: IMB).

Shares in the security, monitoring and risk management services provider closed up 3.5% on Wednesday at 59 cents a share. That sees the Intelligent Monitoring share price up 13.5% in a year.

And according to the analysts at Canaccord Genuity, the ASX All Ords stock is well-placed to deliver earnings growth.

According to the broker:

In its 1Q26 result, IMB reported a 24% increase in its commercial installation pipeline to $45m, indicating strong demand from enterprise customers for security installation and upgrade work. Management noted continued growth in data centre related work as a strong feature and expects to release FY26 guidance in line with market expectations for the first time at its 10 Nov AGM.

Canaccord estimates that management will full year provide guidance for earnings before interest, taxes, depreciation and amortisation (EBITDA) of $48 million, up 25% from FY 2025 earnings.

Canaccord added:

Of note, cash on hand ended 1Q26 at $15.5m and increased to $16.2m as of 30 October despite the $4.2m acquisition payment for BNP securities during the month, reflecting a strong start to 2Q26 cash generation.

The broker said it views the ASX All Ords stock as undervalued at its current FY 2026 estimated EV/EBITDA multiple of 6 times.

Canaccord has a price target of $1.00 a share on Intelligent Monitoring. That represents more than a 69% upside from Wednesday's closing price.

Which brings us to…

Also tipped to rocket

The second ASX All Ords stock that's been tipped to rocket from current levels is Imricor Medical Systems Inc (ASX: IMR).

Shares in the human heart focused healthcare share closed down 0.7% on Wednesday, trading for $1.35 apiece. That sees the Imricor share price up an impressive 51.7% in a year.

And the analysts at Taylor Collison believe it's set to outpace those gains in the year ahead following on the recent groundbreaking heart procedure using Imricor's MRI compatible technology.

The broker noted:

Using Imricor's suite of MRI-compatible products, Amsterdam University Medical Centre (AUMC) successfully performed the world's first real-time MR-guided ischaemic ventricular tachycardia (VT) ablation in a patient with an implantable cardiac defibrillator (ICD)…

This represents a significant de-risking milestone for IMR and validates the clinical potential of MRI-guided electrophysiology (EP) procedures.

Taylor Collison added that this could help pave the way for US FDA approval in the year ahead.

Positive EU data from the VISABL-VT trial demonstrating safe and feasible transeptal crossings in VT patients both with and without ICD's is a significant catalyst for off label VT use in the US after initial FDA approval for atrial flutter (potentially late 2026)

Connecting the dots, the broker has a price target of $2.26 on the ASX All Ords stock. That represents more than a 67% upside from Wednesday's closing price.

The post Top brokers name 2 ASX All Ords stocks tipped to surge 67% and 69% appeared first on The Motley Fool Australia.

The healthcare share price has really come alive in the past 12 months, and has almost doubled to $1.44 per share at the time of writing. The surge on the stock market signals that investors are increasingly excited about what Imricor is achieving in this US$10 billion industry.

World-firsts

So, what makes this US based medical technology company so popular? Imricor is a pioneer that focusses on the heart. It claims to be the first company in the world to deliver commercially viable MRI-compatible consumables for cardiac catheter ablation.

This is a new technology to treat heart rhythm disorders. Unlike traditional X-ray guided ablation, Imricor's iCMR-platform allows doctors to see the heart in real-time. This offers the patient and surgeons potential benefits – better visibility of soft tissues, reduced radiation exposure and improved procedure outcomes.

Last week Imricor claimed to have another world-first when it reported the successful completion of the first MRI-guided ventricular tachycardia (VT) ablation ever performed in real time in a patient with an implantable cardiac defibrillator.

These innovations are obviously good marketing, but more importantly they could really change the way how cardiac ablations are done. If adoption picks up, Imricor's technology could become the new standard in cardiac care.

International ambitions

Imricor's global aspirations are pretty clear. It has identified four key regions where it's executing a rollout: the US, Australia and New Zealand, the Middle East and Europe, where it got CE-Mark approval for its product portfolio.

The company is expanding its base in European countries like Germany, the Netherlands, France and Italy, while it's conducting medical trials in the US to obtain clearance for its products. In the Middle East Imrico has already signed exclusive distributor agreements and it already sold its first products in Qatar.   

In March this year, Imricor completed a capital raise of $70 million to fund the international ambitions, the expansion of commercial operations and research and development.     

Speculative buy

The combination of breakthrough technology and growing clinical validation has pushed the ASX small-cap share to new heights.

Taylor Collison analysts recently retained their outperform recommendation for this speculative investment. Their target price for the healthcare company is $2.26, which implies a 53% upside.

In their latest research note, they comment:

CMR adoption continues to accelerate globally as cardiologists wrestle imaging away from radiologists. With cardiologists demanding their own CMR for deeper tissue, scar, and functional insights – we believe this ultimately positions CMR as the future gold standard for diagnosing and guiding treatment of complex arrhythmias and cardiomyopathies.

The post Is the only way up for this ASX small-cap healthcare stock? appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Domino's Pizza Enterprises Ltd (ASX: DMP)

The Domino's Pizza share price is up 3.5% to $19.02. This pizza chain operator's shares have been storming higher in recent sessions amid takeover speculation. There were reports that Bain Capital had tabled an offer that values the company at $4 billion. And while Domino's advised that it hadn't received an approach, some investors appear to believe there's no smoke without fire.

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up 5% to $4.03. On Monday, this counter drone technology company announced another contract win. DroneShield revealed that it received a $25.3 million contract from a privately owned in-country reseller that is contractually required to distribute the products to a Government defence end customer in a Latin American (LATAM) country. In response to the news, this morning Bell Potter reiterated its buy rating and $5.30 price target on its shares. It said: "We expect 2026 will be an inflection point for the global counter-drone industry with countries poised to unleash a wave of spending on soft-kill detect and defeat solutions. Consequently, we believe DRO should see material contracts flowing from its $2,550m potential sales pipeline over the next 3-6 months as defence budgets roll over to FY26."

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 11% to $1.52. This morning, this medical device company announced the successful completion of the first ischemic ventricular tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. The company stated: " This milestone marks a critical step forward for Imricor's VISABL-VT clinical trial, and a watershed moment for the field of MRI-guided electrophysiology."

Pepper Money Ltd (ASX: PPM)

The Pepper Money share price is up a further 6.5% to $2.54. Investors have been buying this non-bank lender's shares this week after it signed an agreement to acquire the RAMS portfolio from Westpac Banking Corp (ASX: WBC). The portfolio comprises approximately $21.4 billion in residential mortgages. Management highlights that the "transaction aligns with Pepper Money's strategy to grow its capital-light servicing business, which provides annuity-style earnings, operational scale and diversification benefits."

The post Why Domino's, DroneShield, Imricor, and Pepper Money shares are storming higher today appeared first on The Motley Fool Australia.

The fast-rising company in question is Imricor Medical Systems Inc (ASX: IMR).

If you're unfamiliar with the company, Imricor is focused on the human heart.

The company describes itself as "leading the new field of real-time iCMR cardiac ablations – that is, cardiac ablations guided by real-time magnetic resonance imaging (MRI), rather than by conventional x-ray fluoroscopy".

And in morning trade today, the Imricor share price is up 13.6% at $1.55 after the ASX All Ords healthcare share reported on a world-first heart surgery success.

Here's what's happening.

ASX All Ords healthcare share leaps on heart surgery milestone

Imricor shares are charging higher after the company reported the successful completion of the first ischemic ventricular tachycardia (VT) ablation ever performed under real time MRI guidance in an iCMR lab.

The Amsterdam University Medical Centre team performed the VT ablation procedure. According to the release, this followed on previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation procedures guided by real-time MRI and Imricor's NorthStar Mapping System.

Michiel Kemme, who performed the VT ablation, said:

This procedure is part of an international research program. The MRI imaging shows us precisely where the myocardial infarction took place; therefore, we can send the catheter to the exact spot. This information has the potential to make ablation more effective.

The ASX All Ords healthcare share noted that Ischemic VT is among the most challenging and life-threatening arrhythmias. It said conventional VT ablations often take more than eight hours with success rates as low as 40%.

As for the world firsts, Imricor said the procedure involved crossing the septum from the right side of the heart to the left, which had never been performed in a human under MRI guidance before.

And in another world first, the company noted that the ablation lesions were delivered from within the ventricle under real-time MRI guidance.

Kemme said:

Thanks to the interventional MRI, we can see exactly in 3D where the sheath and ablation catheter are. This allowed us to move from the right atrium to the left atrium through the septum. It gives us much more information than the usual method.

Commenting on the successful procedure, Imricor CEO Steve Wedan added:

This is a defining moment for Imricor and for the field of electrophysiology. Performing the world's first ischemic VT ablation entirely inside the MRI validates our core vision, that real-time MR guidance can unlock safer, more effective, and more personalised treatments for patients with complex arrhythmias.

With today's intraday surge focused in, the ASX All Ords healthcare share is up a whopping 107% since this time last year.

The post Guess which ASX All Ords healthcare share is rocketing 14% on a 'world first' success appeared first on The Motley Fool Australia.

That's according to the analysts at Taylor Collison, who recently maintained their outperform rating on Imricor Medical Systems Inc (ASX: IMR).

Imricor shares closed up 1.39% on Monday, trading for $1.46 apiece.

This sees the ASX All Ords healthcare share up 106% in 12 months, smashing the 10.3% gains delivered by the benchmark index over this same period.

Now, here's why Taylor Collison believes Imricor's bull run could have a lot further to go.

What's the latest from Imricor?

If you're not familiar with Imricor, the company describes itself as "leading the new field of real-time iCMR cardiac ablations – that is, cardiac ablations guided by real-time magnetic resonance imaging (MRI), rather than by conventional x-ray fluoroscopy".

The ASX All Ords healthcare share released its September quarter results on 22 October.

Commenting on the quarter just past, Imricor CEO Steve Wedan said on the day:

This was a milestone quarter for Imricor as we achieved parallel regulatory submissions in the US and launched NorthStar commercially in Europe. The 510(k) filings for both NorthStar and the Vision-MR Diagnostic Catheter represent major steps toward bringing MRI-guided electrophysiology to patients and physicians in the US.

Why this ASX All Ords healthcare share could keep leaping higher

Taylor Collison recently participated in the Atrial Fibrillation (AF) Symposium at the University of Adelaide in South Australia.

The broker called it "one of the world's premier forums for electrophysiology innovation".

And the AF Symposium bodes well for Imricor's growth outlook.

"Our engagements with key opinion leaders and industry participants provided strong validation of Imricor's real-time MRI-guided (iCMR) strategy," Taylor Collison said.

The broker added:

Industry and KOL discussions centred on atrial substrate visualisation, advances in AF ablation, and the accelerating commercial momentum in Pulse Field Ablation (PFA)—all areas where Imricor's platform offers a differentiated value proposition.

And this real time MRI guidance could see the ASX All Ords healthcare share doubling its peak sales.

Taylor Collison noted:

Expected benefits of real-time MRI guidance could allow IMR's workflow to move beyond AF re-dos & VT into initial AF ablations, potentially leading to greater total market uptake, boosting peak sales from US$1B – US$2B.

The broker estimates that the global electrophysiology market is worth around US$8 billion. But this market is reported to remain "dominated by X-ray and voltage mapping-based ablation, approaches constrained by limited soft-tissue visibility and persistently high recurrence rates".

Connecting the dots, Taylor Collison maintained its outperform rating on the ASX All Ords healthcare share with a price target of $2.26 a share. That's 55% above the Imricor closing share price on Monday.

The post This ASX All Ords healthcare share more than doubled investors' money in a year. Here's why it's tipped to rocket another 55% appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up a further 3% to $3.29. Investors have been buying this counter drone technology company's shares this week after it released a sales update. DroneShield has surpassed 4,000 systems sold worldwide. This follows the receipt of a package of two standalone contracts totalling $7.9 million for handheld systems for delivery to the U.S. Department of Defense. Commenting on the news, DroneShield's US CEO, Matt McCrann, said: "Passing 4,000 systems in service is an important milestone for our team and our customers. It underlines the performance and dependability of our solutions in the field, and the trust placed in DroneShield by those who rely on them."

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 8% to $1.52. This morning, this medical device company revealed that it has successfully completed its Human Factors (HF) study covering all devices that are currently under review by the U.S. FDA. Imricor's chair and CEO, Steve Wedan, commented: "The scale of this study cannot be overstated, having taken our team over a year from planning through execution. Completing human factors testing across our entire product portfolio is an extraordinary achievement and a clear demonstration of the strength and dedication of the Imricor team. It also marks a major milestone on our path to FDA approval and positions us strongly as we prepare to bring MRI-guided ablation to the United States."

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is up 6% to $8.22. This uranium stock has been charging higher this week amid positive industry news. This includes the US Energy Secretary Chris Wright revealing that his government hopes to see "rapid growth" in consumption of the nuclear fuel, and that the US needed to move away from reliance on Russian-enriched uranium. In addition, the International Atomic Energy Agency (IAEA) upgraded its global nuclear operational capacity estimates.

Silex Systems Ltd (ASX: SLX)

The Silex Systems share price is up a further 16% to $5.57. Investors have been buying this uranium technology company's shares this week after a big update. Silex advised that Global Laser Enrichment (GLE), the exclusive licensee of the SILEX uranium enrichment technology, has completed the large-scale enrichment demonstration testing campaign at its Test Loop facility in North Carolina. The release reveals that GLE has collected extensive performance data providing confidence that its laser-based uranium enrichment process will achieve TRL-6 demonstration status and can be commercially deployed.

The post Why DroneShield, Imricor, Paladin Energy, and Silex shares are pushing higher appeared first on The Motley Fool Australia.

At the time of writing, the ASX stock is up 11% to $1.56.

This means the medical device company's shares are now up over 200% since this time last year.

Why is this ASX stock jumping?

Investors have been buying the company's shares after it released an update on a study and the US Food and Drug Administration (FDA).

Imricor notes that it is aiming to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance.

According to the release, the ASX stock has successfully completed its Human Factors (HF) study covering all devices that are currently under review by the U.S. FDA.

Management notes that the HF study is a critical step in the FDA approval process, as it ensures that each device can be used safely and effectively by clinicians in real-world settings. It believes that completion of this extensive study across the company's full product portfolio represents a major milestone in advancing toward FDA market approval.

It also feels that it highlights both the scale and complexity of the project, which required comprehensive testing across multiple devices, workflows, and clinical scenarios. In addition, it emphasises the strong momentum the ASX stock is building as it continues to progress through the U.S. regulatory pathway.

What's next?

With the HF study now complete, the ASX stock advised that it is one step closer to unlocking access to the world's largest electrophysiology market. Management believes this represents a significant growth opportunity for the company and a major inflection point in its global strategy.

Imricor's chair and CEO, Steve Wedan, commented:

The scale of this study cannot be overstated, having taken our team over a year from planning through execution. Completing human factors testing across our entire product portfolio is an extraordinary achievement and a clear demonstration of the strength and dedication of the Imricor team. It also marks a major milestone on our path to FDA approval and positions us strongly as we prepare to bring MRI-guided ablation to the United States.

I am grateful to the physicians and medical staff that took the time to travel to the Imricor's iCMR Design Centre in Minneapolis to complete this study. They have played an important and vital role in shaping the future of Imricor and of interventional medicine.

The post Guess which ASX stock is surging 11% on big US news appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is down over 2% to $1.17. Investors have been selling this medical technology company's shares this month after it revealed that the US approval process for its 3D MRI mapping system, NorthStar, has been delayed. Morgans remains upbeat, though. It said: "The share price has dropped 20% this morning, which we see as a complete overreaction. Therefore, a great buying opportunity has emerged. There are plenty of catalysts coming over the next few quarters which will drive the share price higher including the expected approval of the NorthStar mapping system. We have made no changes to our forecasts or valuation. We maintain a speculative buy recommendation on IMR."

Imugene Ltd (ASX: IMU)

The Imugene share price is down almost 12% to 37.5 cents. This follows news that the clinical stage immuno-oncology company has received firm commitments from institutional and sophisticated investors for a $22.5 million placement. These funds are being raised through the issue of 68.2 million shares at a 22% discount of 33 cents per new share. The company advised that the proceeds of the capital raising will primarily be used to fund the azer-cel program through to initiating a pivotal clinical trial in 2026. Post completion, Imugene will have a pro-forma cash balance of $64 million. With anticipated R&D rebates and other cost saving initiatives, it expects to have funding into second half of 2026. In addition, the potential exercise of attaching options provides for up to a further $36.6 million of near-term funding.

Newmont Corporation (ASX: NEM)

The Newmont Corporation share price is down 5% to $88.27. Investors have been selling gold miners today after the gold price pulled back overnight. This has seen the S&P/ASX All Ordinaries Gold index weigh heavily on the market today with a 2.5% decline. Despite today's weakness, Newmont Corporation shares are up approximately 46% year to date.

Pepper Money Ltd (ASX: PPM)

The Pepper Money share price is down 3.5% to $1.86. This has been driven by the release of a broker note out of the Macquarie equities desk this morning. According to the note, the broker has downgraded this non-bank lender's shares to a neutral rating with an improved price target of $1.70. While the broker believes that the current environment is favourable for non-bank lenders like Pepper Money, it thinks that this is now firmly priced into its share price.

The post Why Imricor, Imugene, Newmont, and Pepper Money shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is down almost 4% to $1.27. This medical technology company's shares have come under pressure this week. This is despite news that it has received regulatory approval for its 3D MRI mapping system NorthStar in Europe. Investors appear more disappointed that its approval process in the United States has been delayed. The company's chair and CEO, Steve Wedan, remains positive. He said: "We continue to march towards commercialising Imricor's groundbreaking technology across the globe. In Europe the regulatory approvals are now in place, the commercial launch is fully underway, and the sales team are growing and progressing the pipeline."

Ora Banda Mining Ltd (ASX: OBM)

The Ora Banda share price is down almost 11% to 64.7 cents. This gold miner's shares are falling today following the release of a production update and its guidance for FY 2026. Ora Banda advised that gold produced for the quarter totalled 21.9k ounces. This was lower than expected due to the impacts of a slower than planned ramp up of the mill and mining delays at Riverina Underground. Looking ahead, management is guiding to production of 140k ounces to 155k ounces in FY 2026. Managing director, Luke Creagh, said: "Despite the previously announced challenges in the June quarter, the operations and OBM team are set up well going into FY26. This has set a strong platform as FY26 commences our next phase of growth, with production anticipated to increase over 60% to between 140 and 155 thousand ounces."

Ventia Services Group Ltd (ASX: VNT)

The Ventia Services share price is down over 2% to $5.10. This is despite the essential infrastructure services provider announcing an additional fibre upgrade works contract from the NBN. The contract is expected to deliver additional revenue of approximately $280 million to Ventia over the next 3.5 years. Though, it is worth noting that NBN also awarded a $360 million contract to rival Service Stream Ltd (ASX: SSM). It is possible the market was betting on Ventia winning both.

Vulcan Energy Resources Ltd (ASX: VUL)

The Vulcan Energy share price is down 10% to $3.59. This has been driven by the completion of a strategic institutional placement this morning. The lithium developer is raising approximately $53.6 million at a 15% discount of $3.40 per new share. Management notes that proceeds from the placement will be used to maintain and de-risk the execution of critical path scope for development of the Phase One Lionheart Project.

The post Why Imricor, Ora Banda, Ventia, and Vulcan shares are dropping today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

CSL Ltd (ASX: CSL)

The CSL share price is down almost 2% to $239.82. This may have been driven by concerns over US President Donald Trump's plan to impose 200% tariffs on imported pharmaceuticals next year. A number of other ASX pharma stocks are under pressure today and dropping into the red.

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is down 18% to $1.27. This is despite the medical technology company revealing that it has now received regulatory approval for its 3D MRI mapping system NorthStar in Europe. Commenting on the news, the company's chair and CEO, Steve Wedan, said: "We continue to march towards commercialising Imricor's groundbreaking technology across the globe. In Europe the regulatory approvals are now in place, the commercial launch is fully underway, and the sales team are growing and progressing the pipeline." The company also advised that it has "submitted an updated PMA schedule, called a "PMA Shell," to the FDA, targeting final clinical trial data submission to the FDA following submission of the 3rd PMA module in 1H 2026."

Jumbo Interactive Ltd (ASX: JIN)

The Jumbo Interactive share price is down over 3% to $10.06. This appears to have been driven by a broker note out of Citi this morning. According to the note, the broker has downgraded the online lottery ticket seller's shares to a neutral rating (from buy) with a reduced price target of $11.30 (from $14.60). Citi made the move on the belief that weak lottery jackpots could be weighing on its performance.

Netwealth Group Ltd (ASX: NWL)

The Netwealth share price is down 1% to $34.60. Investors have been selling this investment platform provider's shares following the release of a trading update. Netwealth reported total funds under administration (FUA) of $112.8 billion at 30 June 2025. This represents an increase of $8.7 billion for the quarter, including $3.8 billion of FUA net flows and $4.9 billion of positive market movements. While this looks strong on paper, it was notably lower than the market was expecting for the three months.

The post Why CSL, Imricor, Jumbo, and Netwealth shares are falling today appeared first on The Motley Fool Australia.

After all, the potential returns on offer at the small side of the market are much greater than at the large cap side.

But which small cap ASX shares could be buys for investors? Let's take a look at two that analysts at Morgans are bullish on. Here's what they are recommending:

Findi Ltd (ASX: FND)

This India-focused payments company could be a small cap ASX share to buy according to Morgans.

It was relatively pleased with its recent FY 2025 results and believes the company is well-placed for growth over the long term. Particularly given the company's overall build out. It said:

FND's FY25 revenue beat guidance expectations (A$75m vs A$68m to A$70m)., whilst reported EBITDA came in at the mid-point of guidance (A$30m-A$32m). We saw this as a somewhat mixed result. While the headline numbers faired well versus guidance parameters they were assisted by higher "other income."

More positively F25 Operating cashflow generation was strong and FND's India IPO remains on track. We lower our FND FY26F/FY27F EPS by >10% off low bases. […] We think FND management are executing well on the company's overall build out, and with significant upside potential existing to our price target, we maintain our ADD call.

Morgans has an add rating and $7.55 price target on its shares. This suggests that upside of 100% is possible from current levels.

Imricor Medical Systems Inc (ASX: IMR)

Another small cap ASX share that could be a buy according to the broker is Imricor Medical Systems. It is a developer of innovative MRI-compatible medical devices.

The broker was pleased to see that its NorthStar Mapping System has been approved in Europe. Combined with other approvals, it expects its sales to grow at a solid rate in the coming quarters. It said:

IMR has announced approval for its NorthStar Mapping System in Europe. This is a major milestone for the company. We view the mapping system as a key component of its product offering and together with recent other approvals will drive a higher level of sales over subsequent quarters. IMR is well capitalised following the recent capital raising.

We have made no changes to our forecasts and valuation. Our target price remains unchanged at A$2.28. With recent products approved, growing clinician as well as investor interest, and a solid financial position, IMR is one of our key picks in the emerging healthcare sector. We maintain our SPECULATIVE BUY recommendation.

Morgans has a speculative buy rating and $2.28 price target on its shares. This implies potential upside of 44% for investors over the next 12 months.

The post Morgans says these small cap ASX shares can rise 40% to 100% appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Imricor Medical Systems Inc (ASX: IMR)

The Imricor share price is down 3% to $1.41. This is despite the medical systems company releasing some good news this morning. Imricor revealed that its Advantage-MR EP Recorder/Stimulator has received CE mark certification under the European Union's new Medical Device Regulation (MDR). This follows the earlier CE mark approval of Imricor's 2nd generation Vision-MR Ablation Catheter under the MDR regime. Commercial launch of the 2nd generation Vision-MR Ablation Catheter and the new AdvantageMR system is planned to commence in June across the EU.

Nanosonics Ltd (ASX: NAN)

The Nanosonics share price is down 7.5% to $4.48. This may have been driven by a broker note out of Bell Potter this morning. According to the note, the broker has downgraded the medical device company's shares to a sell rating with a $4.05 price target. It said: "With FY26 almost upon us, we note consensus revenues are 5% above our forecast. Forecast revenues are generally highly transparent and we expect minimal contribution from the new CORIS device in FY26, hence our view that consensus revenues are cum downgrade at the August result. The note includes our sum of parts valuation assessment which yields a target price of $4.05, accordingly we downgrade to Sell from Hold."

Perpetual Ltd (ASX: PPT)

The Perpetual share price is down 1.5% to $15.39. This morning, analysts at Citi downgraded the fund manager's shares to a neutral rating (from buy) with a reduced price target of $18.25 (from $24.80). It made the move after running the rule over the company's quarterly update, which was released earlier this week.

Tourism Holdings Ltd (ASX: THL)

The Tourism Holdings share price is down 14% to $1.31. The catalyst for this has been the released of a trading update from the recreational vehicles company. The company warned: "Recent global geopolitical and tariff developments have significantly weakened the operating environment and lead to an additional decline in consumer confidence globally. This decline has resulted in further deterioration in vehicle sales demand, impacting both volumes and margins in all countries."

The post Why Imricor, Nanosonics, Perpetual, and Tourism Holdings shares are sinking today appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back today are listed below. Here's why they are rising:

Antipa Minerals Ltd (ASX: AZY)

The Antipa Minerals share price is up 8% to 47.5 cents. Investors have been buying the company's shares this week after it revealed that IGO Ltd (ASX: IGO) elected to withdraw from the Paterson Project farm-in agreement that was entered into in July 2020. This meant that Antipa Minerals retains 100% ownership of the project which fully surrounds the Minyari Dome Development Project area and its 2.3 million oz of gold and 83,500 tonnes of copper.

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 9% to $1.48. This has been driven by news that the company has commenced the VISABL-VT clinical trial. This follows the completion of the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) with its NorthStar Mapping System. The procedure was successfully performed by the team at Amsterdam University Medical Centre (AUMC), ranked in 2025 by Newsweek as the best hospital in The Netherlands, and in the top 35 worldwide.

Lynas Rare Earths Ltd (ASX: LYC)

The Lynas Rare Earths share price is almost 2% to $7.85. This is despite the rare earths producer copping a downgrade from Bell Potter this morning. It downgraded its shares to a sell rating with a reduced price target of $6.50. It said: "Whilst we like the business, asset, and team, we believe there is significant optimism priced into the stock. Historically, LYC has responded to earnings revisions, however the market has looked through that for the past 12 months. We do not see risks to the balance sheet under our price deck, however a lower-for-longer NdPr price could draw attention."

Newmont Corporation (ASX: NEM)

The Newmont Corporation share price is up 4.5% to $82.65. Investors have been buying the gold miner's shares today following a strong rise in the price of the precious metal overnight. The buying was so strong that the gold price hit a new record high. Investors were buying it due to increased demand for safe haven assets and a lower than expected US inflation reading.

The post Why Antipa, Imricor, Lynas, and Newmont shares are pushing higher today appeared first on The Motley Fool Australia.